Physician profile
Daniel Denison
NPI 1871637264
$2,335.74
in general payments reported to CMS, 2019-2025
12 companies · $61.17 in 2025
The $61.17 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $104 · 2021: $120 · 2022: $208 · 2023: $59.10 · 2024: $1,522 · 2025: $61.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829 · Travel and Lodging: $804 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.27 |
| Travel and Lodging | $804.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,633.31 | 2019-2024 | |
| Kerecis Limited | $154.15 | 2022 | |
| Smith+Nephew, INC. | $137.82 | 2019-2021 | |
| Sanara Medtech INC. | $85.61 | 2020-2021 | |
| Allergan, INC. | $78.25 | 2019-2022 | |
| Aroa Biosurgery Incorporated | $59.90 | 2024-2025 | |
| Hologic Sales and Service, LLC | $53.65 | 2022-2024 | Localizer |
| Abbvie INC. | $42.52 | 2023-2024 | Strattice Reconstructive Tissue Matrix Bps |
| Lemaitre Vascular, INC. | $27.61 | 2019-2023 | Artegraft Vascular Graft |
| Pacira Pharmaceuticals Incorporated | $24.23 | 2023 | Exparel |
| Integra Lifesciences Corporation | $20.76 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Baxter Healthcare | $17.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Denison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.